Tower Research Capital (TRC)’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Tower Research Capital (TRC)’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-81,647	Closed	-$8K	–	4942
2016 Q3	$8K	Buy	81,647 +54,196	+197%	+$11.8K	﹤0.01%	2282
2016 Q2	$10K	Buy	27,451 +25,325	+1,191%	+$9.63K	﹤0.01%	2880
2016 Q1	$1K	Buy	2,126 +1,771	+499%	+$729	﹤0.01%	3960
2015 Q4	$0	Buy	+355	New	+$168	﹤0.01%	5546
2015 Q3	–	Sell	-5	Closed	–	–	5362
2015 Q2	$0	Hold	5	–	–	﹤0.01%	5492
2015 Q1	$0	Sell	5 -10	-67%	-$8	﹤0.01%	5329
2014 Q4	$0	Hold	15	–	–	﹤0.01%	5225
2014 Q3	$0	Hold	15	–	–	﹤0.01%	5239
2014 Q2	$0	Buy	+15	New	+$18	﹤0.01%	5082

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Tower Research Capital (TRC)'s PVCT Position: Q4 2016 in Review

Tower Research Capital (TRC) sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 81,647 shares — an estimated $8K sold.

Tower Research Capital (TRC) first reported a position in PVCT in Q2 2014 and held it in 9 quarters. The position peaked at $10K in Q2 2016. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Tower Research Capital (TRC) reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 81,647 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $8K.
Tower Research Capital (TRC) first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 9 quarters.
Tower Research Capital (TRC)'s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $10K in Q2 2016.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2016, filed 3 Feb 2017.